Tenaya Therapeutics (TNYA) announced that new interim safety and efficacy data from the company’s MyPEAK-1 Phase 1b/2a clinical trial of TN-201 were presented today during the Late-Breaking Science: Main Event session at the American Heart Association’s, AHA, Scientific Sessions 2025. These data, which included longer-term follow-up results for three patients dosed with TN-201 gene therapy at a dose of 3E13vg/kg and initial results for three patients who received TN-201 at a dose of 6E13 vg/kg were simultaneously published in Cardiovascular Research. Key findings: MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research; TN-201 Has Been Generally Well Tolerated at Both Doses; Longer-term Follow Up of Cohort 1 Patients Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy; Initial Cohort 2 Data Demonstrated Early Dose Responsive Increases in TN-201 Transduction and MyBP-C Protein Expression
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNYA:
- FDA Places Hold on Tenaya’s MyPEAKTM-1 Trial
- Promising Developments in Tenaya Therapeutics’ MyPEAK-1 Study Support Buy Rating
- Tenaya Therapeutics Advances Genetic Therapy for Heart Disease: A Closer Look at the TN-201 Study
- Tenaya Therapeutics Advances Gene Therapy Study for ARVC
- Tenaya Therapeutics Advances Pediatric Cardiomyopathy Research with New Study Update